Therapeutic Action
Hormonal contraceptive, progestogen
PDF page 446
Drug reference
Hormonal contraceptive, progestogen
PDF page 446
Long-acting contraception Long-term treatment of functional uterine bleeding
PDF page 446
Do not administer to patients with breast cancer, severe hypertension (≥ 160/100), active thromboembolic disorders, uncontrolled or complicated diabetes, severe or recent hepatic disease. May cause: menstrual irregularities, amenorrhoea, menometrorrhagia, breast tenderness, headache, weight gain, acne, mood change, abdominal pain, gastrointestinal disturbances. The contraceptive efficacy of medroxyprogesterone does not seem to be reduced in women taking enzyme-inducing drugs. Pregnancy: CONTRA-INDICATED Breast-feeding: no contra-indication
PDF pages 446, 447
150 mg in 1 ml vial (150 mg/ml) for IM injection
PDF page 446
Adolescent and adult: 150 mg every 3 months (13 weeks). Subsequent injections may be administered up to 2 weeks before or 4 weeks after the scheduled date. The injection may be administered at any moment of the cycle if it is reasonably certain the woman is not pregnant, including when switching from another form of contraception. For contraception, use condoms for 7 days after the injection if it is administered: more than 7 days after the start of menstruation; more than 28 days postpartum if not breastfeeding; more than 7 days after an abortion.
PDF page 446
Contraception: as long as this method of contraception is desired and well tolerated. Long-term treatment of functional uterine bleeding: according to clinical response.
PDF page 446
Shake the vial vigorously before use to homogenise the suspension. Return to fertility is delayed for 3 to 12 months after stopping injections. Also comes in prefilled single-use injection system (104 mg/0.65 ml) for SC self-administration in the abdomen or anterior thigh.
PDF page 447
– Below 25 °C
PDF page 447
150 mg every 3 months (13 weeks). Subsequent injections may be administered up to 2 weeks before or 4 weeks after the scheduled date.
PDF page 446